MENU
IMRN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Immuron (IMRN) Ownership - Who owns Immuron?
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
Chapman Street
Phone
+61 398245254
Employees
6
Web
https://www.immuron.com.au
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
9.15M
P/E Ratio
N/A
Total Cash
7.74M
Projected Growth
N/A
Total Debt
N/A
Revenue
6.54M
Risk (Beta)
1.40
Dividend Yield
N/A
Total Cash/Share
1.35
Total Debt/Equity
N/A
Revenue/Share
0.72 USD as % of share price
Fundamentals
IMRN
Capitalization
9.15M
P/E Ratio
N/A
Risk (Beta)
1.40
Dividend Yield
N/A
Total Cash
7.74M
Total Cash/Share
1.35
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.72%
Revenue
6.54M
ROE
N/A
Book Value
10.3M
P/B Ratio
1.55
Cash Flow
N/A
Earnings
-1.29
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
88.6M
Current Ratio
6.80
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-7.35M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-45.88
Shares Held By Institutions
10.5K
Shares Outstanding - Current
5.73M
Total Liabilities
1.83M
Total Volume MTD
N/A
Value
1
Gain YTD
2.941
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
Chapman Street
Phone
+61 398245254
Employees
6
Web
https://www.immuron.com.au